Carprofen is a non-steroidal anti-inflammatory drug (NSAID) that has been found to have antimicrobial activity. Carprofen is primarily used as a veterinary analgesic and anti-inflammatory for arthritis and pain. Its anti-inflammatory activity is due to cyclooxygenase inihbition with selectivity for COX-2 inhibition, while its antimicrobial activity is less certain. Carprofen can kill B. subtilis by permeabilizing its membrane. Other studies have shown carprofen can target the Escherichia coli DNA polymerase III β subunit.
British medical bulletin, 118(1), 138-148 (2016-05-07)
The number of cases of drug-resistant Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), has risen rapidly in recent years. This has led to the resurgence in repurposing existing drugs, such as non-steroidal anti-inflammatory drugs (NSAIDs), for anti-TB treatment. Evidence
Evidence suggests that some nonsteroidal anti-inflammatory drugs (NSAIDs) possess antibacterial properties with an unknown mechanism. We describe the in vitro antibacterial properties of the NSAIDs carprofen, bromfenac, and vedaprofen, and show that these NSAIDs inhibit the Escherichia coli DNA polymerase III
ACS chemical biology, 11(8), 2222-2231 (2016-05-20)
Increasing antimicrobial resistance has become a major public health crisis. New antimicrobials with novel mechanisms of action (MOA) are desperately needed. We previously developed a method, bacterial cytological profiling (BCP), which utilizes fluorescence microscopy to rapidly identify the MOA of
American journal of obstetrics & gynecology MFM, 2(2), 100084-100084 (2020-12-22)
Accurate prediction of spontaneous preterm labor/preterm birth in asymptomatic women remains an elusive clinical challenge because of the multi-etiological nature of preterm birth. The aim of this study was to develop and validate an immunoassay-based, multi-biomarker test to predict spontaneous preterm
Colorectal cancer (CRC) is a challenging disease, with a high mortality rate and limited effective treatment options, particularly for late-stage disease. Patient-derived xenografts (PDXs) have emerged as an informative, renewable experimental resource to model CRC architecture and biology. Here, we
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
